Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979241 | 0.92 | CES1 (0.44) | APEX1CES2CES1TP53MEN1 | |
| SCHEMBL88045 | 0.88 | CES1 (0.48) | APEX1CES2CES1TP53MEN1 | |
| SCHEMBL8089512 | 0.88 | CES1 (0.48) | APEX1CES2CES1TP53MEN1 | |
| SCHEMBL3103935 | 0.84 | GPR84 (0.52) | APEX1CES2CES1MEN1KMT2A | |
| SCHEMBL12095977 | 0.84 | AKR1B1 (0.52) | APEX1CES2CES1MEN1KMT2A | |
| SCHEMBL1537455 | 0.82 | CES1 (0.42) | APEX1CES2CES1TP53MEN1 | |
| SCHEMBL7037735 | 0.80 | CES1 (0.41) | APEX1CES2CES1TP53MEN1 | |
| SCHEMBL9189325 | 0.78 | ALDH1A1 (0.46) | APEX1CES2CES1TP53MEN1 | |
| SCHEMBL2940335 | 0.78 | CES1 (0.40) | APEX1CES2CES1TP53MEN1 | |
| SCHEMBL3148391 | 0.77 | FFAR3 (0.42) | CES2CES1GRIK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795450-B2 | Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100048711-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-7405311-B2 | Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070197659-A1 | Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-7211667-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070010535-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates | MAGNESIUM DIAGNOSTICS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010535-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates | ECE1, GLS, ECE2 | APEX1 235/4885CES2 1675/4885CES1 714/4885 |
| US-20100048711-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | APEX1 1473/4885CES2 2656/4885CES1 880/4885 |
| US-20070197659-A1 | Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MEN1 | APEX1 1646/4885CES2 2770/4885CES1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.